The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

It is not certain that the new Wearable Behaviour Model (WBM) AI will make it into a finished product – not least because of ...

Barbie just took a step forward for inclusivity and representation with the launch of a doll with type 1 diabetes.

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on PD-1xVEGF bispecific ivonescimab that is estimated to be worth as much ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie.

The weather was hot in London for this year’s LSX World Congress – but what was the atmosphere like at Europe’s leading partnering, strategy, and investment event?

After months of preparation and a drip-feed of some of its key features, the UK government has raised the curtain on its new 10-year plan for the NHS. The three over-arching themes are already ...

Is chaos in US health policy creating new global opportunities? With major leadership and policy shake-ups the US healthcare ...

Technology has also improved immunisation operations with the use of online appointment scheduling that automates ...

It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...

From robot-assisted surgery to personalised disease treatment - technology can do some truly remarkable things. But while the ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared the oral neurokinin (NK) 1 and 3 antagonist, under the Lynkuet brand name, for the treatment of moderate to severe vasomotor ...